The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TMO | +3.08% | +20.77% | +3.84% | +22,276% |
| S&P | +16.9% | +95.99% | +14.39% | +5,398% |
Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $11.12B | 4.9% |
| Gross Profit | $4.22B | -2.9% |
| Gross Margin | 37.92% | -3.1% |
| Market Cap | $183.15B | -22.5% |
| Market Cap / Employee | $1.47M | 0.0% |
| Employees | 125K | 2.5% |
| Net Income | $1.63B | 0.1% |
| EBITDA | $2.74B | 3.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.98B | -57.4% |
| Accounts Receivable | $8.91B | -9.0% |
| Inventory | 5.7K | 5.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $31.86B | 2.1% |
| Short Term Debt | $3.82B | -7.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 6.47% | 0.3% |
| Return On Invested Capital | 9.40% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $1.84B | -3.1% |
| Operating Free Cash Flow | $2.24B | 3.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 31.49 | 29.35 | 23.63 | 26.83 | -30.37% |
| Price to Book | 4.06 | 3.82 | 3.10 | 3.63 | -27.22% |
| Price to Sales | 4.65 | 4.42 | 3.57 | 4.01 | -27.95% |
| Price to Tangible Book Value | -14.22 | -16.05 | -12.32 | -15.41 | -22.20% |
| Price to Free Cash Flow TTM | 29.81 | 30.94 | 27.76 | 31.98 | -2.35% |
| Enterprise Value to EBITDA | 75.26 | 85.61 | 69.60 | 75.87 | -23.87% |
| Free Cash Flow Yield | 3.4% | 3.2% | 3.6% | 3.1% | 2.41% |
| Return on Equity | 13.2% | 13.7% | 13.4% | 13.2% | 1.15% |
| Total Debt | $32.78B | $34.19B | $35.23B | $35.68B | 1.04% |
TMO earnings call for the period ending December 31, 2024.
TMO earnings call for the period ending September 30, 2024.
TMO earnings call for the period ending June 30, 2024.
TMO earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
